Lexicon Buys Back GI Drugs from Symphony Capital, But Plenty of Risk Remains
This article was originally published in The Pink Sheet Daily
Executive Summary
With only $10 million upfront, the buyback is not an exit for Symphony. For the project financier to make money anytime soon from its 2007 investment, Lexicon now has to find a licensing partner.